Business
Recursion Publishes Second Annual Environmental, Social and Governance Report
Highlights include the company’s significant progress in 2022 to create a more sustainable R&D model and advance potential new medicines to patients Salt Lake
About this update from Recursion Pharmaceuticals, Inc.
[{"type":"text","content":"Highlights include the company’s significant progress in 2022 to create a more sustainable R&D model and advance potential new medicines to patients\nSalt Lake City, March 28, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today announced the release of its second annual Environmental, Social and Governance (ESG) Report. The report highlights the company’s approach, practices and goals in several important areas such as its commitment to patients, social and community impact, people and culture, environmental sustainability, and governance. “As a company focused on using cutting-edge technology to find solutions to some of the most complex and pressing problems in biotechnology, we have the opportunity to create massive positive impact in the world and build an incredible business to drive it,” said Chris Gibson, Ph.D., Co-Founder and Chief Executive Officer at Recursion. “In our second annual ESG report, we outline how our work in 2022 to industrialize drug discovery is in direct support of our vision to create a more sustainable future - not only to benefit patients, but also our employees, partners, communities, and the broader healthcare and technology innovation ecosystems.” Since publishing its inaugural ESG report last year, Recursion has received several recognitions for its commitment to excellence in ESG. Institutional Shareholder Services (ISS) awarded Recursion a Prime Rating for ESG performance in 2022, which recognizes companies with ESG performance above a sector-specific threshold and is defined by ISS as \"absolute best in class.\" Additionally, as of October 2022, Recursion was ranked 98 out of over 850 companies (approximately top 10%) in the pharmaceutical category by Morningstar Sustainalytics, which gives an in-depth analysis of a company’s ESG performance and compares it to industry peers. In February 2023, Recursion received an MSCI ESG Rating of A. Recursion’s ESG Report is guided by key ESG frameworks, notably the standards of the Sustainability Accounting Standards Board (SASB) and the United Nations Sustainable Development Goals (UN SDGs). You can learn more about Recursion’s approach to ESG and download a copy of the report at www.Recursion.com/esg. About Recursion Recursion is a clinical stage...